Breakthrough Alzheimer updates: UK adaptive platform trial tests repurposed drugs, new phase 2/3 therapies advance, and sleep disruption emerges as a treatable risk factor.
News|Articles|December 31, 2024
Poll Results: Mental Health Clinicians at the Holidays
Author(s)Psychiatric Times Editors
Listen
0:00 / 0:00
Key Takeaways
- The survey highlighted diverse opinions on the holiday season, revealing both positive and negative experiences among mental health professionals.
- Respondents discussed the impact of the holidays on mental health, professional responsibilities, and personal lives, emphasizing the complexity of emotions.
How do your fellow clinicians feel about the holidays? Are they feeling the effects of burnout heading into 2025? Find out here.
Advertisement
Earlier this month, we asked the readers of Psychiatric Times a few questions related to the holidays. Here's how you all answered...
Advertisement
Related to this article
Behind the scenes at a psychiatry conference, Gus Alva, MD, DFAPA, and Erin Crown share practical insights on burnout, industry, and emerging treatments—turning continuing education into better patient outcomes.
Phase 2 trial shows daridorexant boosts pediatric insomnia sleep time up to 50 minutes, including ADHD/ASD patients, with strong safety and phase 3 plans.
New automated connectomics maps synapses across circuits, revealing how inhibitory neuron subtypes shape decision-making and may explain circuit dysfunction in psychiatric disorders.
FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.
Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Synapse-Level Mapping Could Reveal How Disrupted Brain Circuits Lead to Psychiatric Disorders
2
FDA Aligns on Key Elements of Phase 3 Study of Zervimesine for Dementia With Lewy Bodies
3
Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia
4
Daridorexant, Orexin Receptor Agonist, Shows Positive Results in Pediatric Insomnia
5